SCHEMBL23827328

SCHEMBL23827328

COc1ccc(C(OC[C@@]23CN[C@@H]([C@H](n4cnc5c(=O)[nH]c(NC(=O)C(C)C)nc54)O2)[C@@H]3O[Si](C)(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 6/20 0.42
▸ KDM4E B2RXH2 1/20 0.39
▸ TAS1R3 Q7RTX0 1/20 0.34
▸ TAS1R1 Q7RTX1 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ TAAR1 Q96RJ0 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ NT5E P21589 1/20 0.32
▸ PDE9A O76083 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ CDK5R1 Q15078 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24177252 0.96 TYMP (0.41) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL23827249 0.87 TYMP (0.40) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL24513002 0.85 TYMP (0.45) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL19362152 0.85 TYMP (0.45) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL1096942 0.85 TYMP (0.45) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL20393990 0.84 CDK5 (0.36) TYMPCDK5CDK5R1ADORA3
SCHEMBL30898738 0.84 CDK5 (0.36) TYMPCDK5CDK5R1ADORA3
SCHEMBL25630145 0.83 TYMP (0.42) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL23827271 0.83 TYMP (0.43) TYMPKDM4ETAS1R3TAS1R1HPGD
SCHEMBL24177253 0.82 TYMP (0.39) TYMPKDM4ETAS1R3TAS1R1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340584-A1 CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-11-06 — — US disclosed
CN-119119156-A Bridged artificial nucleic acid ALNA 田边三菱制药株式会社 2024-12-13 — — CN disclosed
CN-112996522-B Bridged artificial nucleic acid ALNA 田边三菱制药株式会社 2024-09-20 — — CN disclosed
CN-117964674-A Bridged artificial nucleic acid ALNA 田边三菱制药株式会社 2024-05-03 — — CN disclosed
CN-117964673-A Bridged artificial nucleic acid ALNA 田边三菱制药株式会社 2024-05-03 — — CN disclosed
EP-4275689-A2 CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA Mitsubishi Tanabe Pharma Corporation (JP) 2023-11-15 — — EP disclosed
EP-3881851-A1 CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA Mitsubishi Tanabe Pharma Corporation (JP) 2021-09-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340584-A1 CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA POLN, DDX21, MUS81 TYMP 1322/4885KDM4E 3126/4885TAS1R3 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback